Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Yokouchi, Hiroshi ^a,g   Yamazaki, Koichi ^a,g   Kinoshita, Ichiro ^b,g   Konishi, Jun ^a,g   Asahina, Hajime ^a,g   Sukoh, Noriaki ^c,g   Harada, Masao ^c,g   Akie, Kenji ^d,g   Ogura, Shigeaki ^d,g   Ishida, Takashi ^e,g   Munakata, Mitsuru ^e,g   Dosaka Akita, Hirotoshi ^b,g   Isobe, Hiroshi ^c,f,g   Nishimura, Masaharu ^a,g  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO CANCER CENTER   (Japan)

^d SAPPORO CITY GENERAL HOSPITAL   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f KKR Sapporo Medical Center   (Japan)

^g Hokkaido Lung Cancer Clinical Research Group   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMRUBICIN; CARBOPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PLEURA EFFUSION; RETREATMENT; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; BONE TUMOR; BRAIN TUMOR; COHORT ANALYSIS; DRUG ADMINISTRATION; FOLLOW UP; LIVER TUMOR; LUNG TUMOR; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947731875     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-51     Document Type: Article

References (32)

1. Fukuoka M Yano S Giaccone G Tamura T Nakagawa K Douillard JY Nishiwaki Y Vansteenkiste J Kudoh S Rischin D Eek R Horai T Noda K Takata I Smit E Averbuch S Macleod A Feyereislova A Dong RP Baselga J Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 2003 21 2237-46 10.1200/JCO.2003.10.038 12748244
2. Kris MG Natale RB Herbst RS Lynch TJ Prager D Belani CP Schiller JH Kelly K Spiridonidis H Sandler A Albain KS Cella D Wolf MK Averbuch SD Ochs JJ Kay AC Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer JAMA 2003 290 2149-58 10.1001/ jama.290.16.2149 14570950
3. Ochs J Grous J Warner KL Final survival and safety results for 21,064 non-small cell lung cancer (NSCLC) patients who received compassionate use gefitinib (Iressa®) in a United States expanded access program (EAP) Proc Am Soc Clin Oncol 2004 23 628
4. Janne PA Gurubhagavatula S Yeap BY Lucca J Ostler P Skarin AT Fidias P Lynch TJ Johnson BE Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD 'Iressa') on and expanded access study Lung Cancer 1839 44 221-30 10.1016/j.lungcan.2003.12.014
5. Santoro A Cavina R Latteri F Zucali PA Ginanni V Campagnoli E Ferrari B Morenghi E Pedicini V Roncalli M Alloisio M Ravasi G Soto Parra HJ Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer Ann Oncol 2004 15 33-7 10.1093/annonc/mdh010 14679116
6. Park J Park BB Kim JY Lee SH Lee SI Kim HY Park SH Lee KE Park JO Kim K Jung CW Park YS Im YH Kang WK Lee MH Park K Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer Clin Cancer Res 2004 10 4383-8 10.1158/ 1078-0432.CCR-04-0189 15240526
7. Konishi J Yamazaki K Kinoshita I Isobe H Ogura S Sekine S Ishida T Takashima R Nakadate M Nishikawa S Hattori T Asahina H Imura M Kikuchi E Kikuchi J Shinagawa N Yokouchi H Munakata M Dosaka-Akita H Nishimura M Analysis of the response and toxicity to gefitinib of non-small cell lung cancer Anticancer Res 2005 25 435-42 15816608
8. Simon GR Ruckdeschel JC Williams C Cantor A Chiappori A Rocha Lima CM Antonia S Haura E Wagner H Robinson L Sommers E Alberts M Bepler G Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: Experience from a single institution Cancer control 2003 10 388-95 14581894
9. Lee DH Han JY Lee HG Lee JJ Lee EK Kim HY Kim HK Hong EK Lee JS Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers Clin Cancer Res 2005 11 3032-7 10.1158/1078-0432.CCR-04-2149 15837758
10. Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW Harris PL Haserlat SM Supko JG Haluska FG Louis DN Christiani DC Settleman J Haber DA Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004 350 2129-39 10.1056/NEJMoa040938 15118073
11. Paez JG Janne PA Lee JC Tracy S Greulich H Gabriel S Herman P Kave FJ Lindeman N Boggon Tj Naoki K Sasaki H Fujii Y Eck MJ Sellers WR Johnson BE Meyerson M EGFR mutations in lung cancer; correlation with clinical response to gefitinib therapy Science 2004 304 1497-500 10.1126/ science.1099314 15118125
12. Cappuzzo F Hirsch FR Rossi E Bartolini S Ceresoli GL Bemis L Haney J Witta S Danenberg K Domenichini I Ludovini V Magrini E Gregorc V Doglioni C Sidoni A Tonato M Franklin WA Crino L Bunn PA Varella-Garcia M Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 2005 97 643-55 15870435
13. Cappuzzo F Magrini E Ceresoli GL Bartolini S Rossi E Ludovini V Gregorc V Ligorio C Cancellieri A Damiani S Spreafico A Paties CT Lombardo L calandri C Bellezza G Tonato M Crino L Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 2004 15 1133-41
14. Engelman JA Janne PA Mermel C Pearlberg J Mukohara T Fleet C Cichowski K Johnson BE Cantley LC ErbB-3 mediates phosphoinositide 3-kinase activity in gefitnib-sensitive non-small cell lung cancer cell lines Proc Natl Acad Sci USA 2005 102 3788-93 553328 15731348 10.1073/pnas.0409773102
15. Mitsudomi T Kosaka T Endoh H Horio Y hida T Mori S Hatooka S Shinoda M Takahashi T Yatabe Y Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 2005 23 2513-20 10.1200/JCO.2005.00.992 15738541
16. Han SW Kim TY Hwang PG Jeong S Kim J choi IS Oh DY Kim JH Kim DW Chung DH Im SA Kim YT Lee JS Heo DS Bang YJ Kim NK Predictive and prognostic impact of epidermal growth factor receptor mutation on non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 2005 23 2493-501 10.1200/JCO.2005.01.388 15710947
17. Hirsch FR Garcia MV McCoy J West H Xavier AC Gumerlock P Bunn PA Franklin WA Crowley J Gandara DR Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A southwest oncology group study J Clin Oncol 2005 23 6838-45 10.1200/JCO.2005.01.2823 15998906
18. Tokumo M Toyooka S Kiura K Shigematsu H Tomii K Aoe M Ichimura K Tsuda T Yano M Tsukuda K Tabata M Ueoka H Tanimoto M Date H Gazdar AF Shimizu N The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 2005 11 1167-73 15709185
19. Kim KS Jeong JY Kim YC Na KJ Kim YH Ahn SJ Baek SM Park CS Park CM Kim YI Lim SC Park KO Predictors of the response to gefitinib in refractory non-small cell lung cancer Clin Cancer Res 2005 11 2244-51 10.1158/ 1078-0432.CCR-04-2081 15788673
20. Chou TY Chiu CH Li LH Hsiao CY Tzen CY Chang KT Chen YM Perng RP Tsai SF Tsai CM Mutations in the tyrosine kinase domain of epidermal growth factor receptor is a predictive factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 2005 11 3750-7 10.1158/1078-0432.CCR-04-1981 15897572
21. Takano T Ohe Y Sakamoto H Tsuta K Matsuno Y Tateishi U Yamamoto S Nokihara H Yamamoto N Sekine I Kunitoh H Shibata T Sakiyama T Yoshida T Tamura T Epidermal growth factor receptor gene mutations and increased copy number predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 2005 23 6829-37 10.1200/ JCO.2005.01.0793 15998907
22. Rielly GJ Pao W Pham D Li AR Rizvi N Venkatraman ES Zakowski MF Kris MG Ladanyi M Miller VA Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib and erlotinib Cin Cancer Res 2006 12 839-44
23. Histopathological Typing of Lung and Pleural Tumors International Histological Classification of Tumors World Health Organization. Geneva 3 1999
24. Therasse P Arbuck SG Eisenhauer EA Wanders J Kaplan RS Rubinstein L Verweij J Van Glabbeke M van Oosterom AT Christian MC Gwyther SG New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 2000 92 205-16 10.1093/jnci/92.3.205 10655437
25. Kurata T Tamura K Kaneda H Nogami T Uejima H Asai G Nakagawa K Fukuoka M Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance Ann Oncol 2004 15 173-7 10.1093/annonc/mdh006 14679138
26. Kobayashi S Boggon TJ Dayaram T Janne PA Kocher O Meyerson M Johnson BE Eck MJ Tenen DG Halmos B EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 2005 352 786-92 10.1056/ NEJMoa044238 15728811
27. Pao W Miller VA Politi KA Riely GJ Somwar R Zakowski MF Kris MG Varmus H Acquired resistance of lung adenocarcinoma to gefitinib of erlotinib is associated with a second mutation in the EGFR kinase domain Plos Med 2005 2 1-11 10.1371/journal.pmed.0020001
28. Pao W Wang TY Riely GJ Miller VA Pan Q Ladanyi M Zakowski MF Heelan RT Kris MG Varmus HE KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib Plos Med 2005 2 57-61 10.1371/ journal.pmed.0020057
29. Jain A Tindell CA Laux I Hunter JB Curran J Galkin A Afar DE Aronson N Shak S Natale RB Agus DB Epithelial membrane protein-1 is a biomarker of gefitinib resistance Proc Natl Acad Sci USA 2005 102 11858-63 1187965 16087880 10.1073/pnas.0502113102
30. Omuro AMP Kris MG Miller VA Franceschi E Shah N Milton DT Abrey LE High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Cancer 2005 103 2344-8 10.1002/cncr.21033 15844174
31. Cella D Herbst RS Lynch TJ Prager D Belani CP Schiller JH Heyes A Ochs JS Wolf MK Kay AC Kris MG Natale RB Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial J Clin Oncol 2005 23 1-9 10.1200/JCO.2005.05.153 15545667
32. Hotta K Matsuo K Ueoka H Kiura K Tabata M Harita S Gemba K Yonei T Bessho A Tanimoto M Continued gefitinib treatment after disease stabilization prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience Ann Oncol 2005 16 1817-23 10.1093/annonc/mdi369 16157622